Compare Palantir Technologies Inc (PLTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs TransMedics Group Inc — how do they compare? Palantir Technologies Inc trades at $200.41 (market cap $477.68B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Palantir Technologies Inc is far larger — about 174.3× TransMedics Group Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and TransMedics Group Inc for 24 Days on average.
| PLTR | TMDX | |
|---|---|---|
Market Cap | $477.68B | $2.74B |
Volume | 41,744,992 | 949,331 |
Sector | Technology | Health |
52-Week High | $207.18 | $150.42 |
52-Week Low | $107.27 | $61.99 |
Typical Hold Time | 78 Days | 24 Days |
Enterprise Value | $468.48B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $194.04, up 1.02% with a bullish technical outlook and strong fundamental momentum. The stock shows robust revenue growth of 56.2% in 2025, reaching $4.48 billion, with net income surging to $1.63 billion. Recent partnerships with Armada for sovereign AI infrastructure and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 165.91.
The outlook remains positive with analyst consensus at Buy (53.84%) and a $191.69 price target. Key opportunities include AI platform expansion and commercial customer growth to 870, while risks involve high valuation sensitivity and competitive pressures. The stock trades near recent highs with support at $191 and resistance at $195.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
